Actively Recruiting

Age: 18Years +
All Genders
ID06755775

PET Imaging Targeting Granzyme B to Predict Immunotherapy Response in Diffuse Large B-Cell Lymphoma An Observational Study

Led by Ruijin Hospital · Updated on 2025-01-01

150

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying how PET imaging that targets granzyme B can predict how well immunotherapy works for patients with diffuse large B-cell lymphoma (DLBCL). This study focuses on patients receiving immunotherapy treatments such as CAR-T, Glofitamab, or iR2. The goal is to see if PET scans can help forecast treatment outcomes. Participants will undergo PET scans using 68Ga-grazytracer both before starting immunotherapy and after completing one course of treatment. Medical records will be created for each participant, including their basic information, contact details, and medical history. The study tracks uptake values from these scans at baseline and two weeks after treatment. During the study, researchers will collect and record participant data, perform PET imaging assessments, and monitor treatment effects. They will measure standardized uptake values and the ability of PET scans to predict immunotherapy success. The information gathered will help evaluate the imaging method's usefulness in managing DLBCL patients.

CONDITIONS

Official Title

PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathologic diagnosis of DLBCL
  • General condition is good with expected survival greater than six months
  • Signed and dated informed consent form
Not Eligible

You will not qualify if you...

  • Presence of other malignant tumors
  • Serious medical conditions deemed unsuitable by the investigator
  • Pregnant or breastfeeding women, and women at risk of pregnancy
  • Poor compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School

Shanghai, China

Actively Recruiting

Loading map...

Research Team

X

Xinyi Zhu

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase 3b, Multicenter, Open-label Study of Oral Ibrutinib ...

Chronic Lymphocytic Leukemia

Actively Recruiting

175 locations

A Phase 3 Study of SHR-A1912 Combined With Rituximab, Gemcit...

Diffuse Large B-cell Lymphoma

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here